By Hugo Francisco de Souza Reviewed by Susha Cheriyedath, M.Sc. Feb 11 2026 A novel CAR-T cell approach targets amyloid plaques in preclinical Alzheimer models, raising the possibility that engineered immune therapies could reshape future treatment strategies while major clinical questions remain. Study: Engineering chimeric antigen receptor CD4 T cells for Alzheimer’s disease . Image Credit: Andrii Vodolazhskyi / Shutterstock In a recent study published in  Proceedings of the National Academy